CFAST Sparks Pathways for Developing New Therapeutics for Unmet Patient Needs. Development of Standards Aid FDA in Meeting Commitments under PDUFA V.Continue reading
Author Archive: AZBio
Mark C. Miller Joins Accelerate Diagnostics Board of Directors
TUCSON, Ariz., Nov. 6, 2013 — Accelerate Diagnostics, Inc. , an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug resistant organisms and hospital acquired infections, announced today that Mark C. Miller has been appointed to its Board of Directors.
Mr. Miller currently serves as Executive Chairman and director of Stericycle where he was Chief Executive Officer from 1992 to 2012 and Chairman of the Board of Directors from 2008 to 2012. During his 20 years as CEO, Mark grew Stericycle’s revenues from $1.6 million to $1.9 billion, and in 2009 was selected by Morningstar, Inc. as its “CEO of the Year.” Prior to joining Stericycle, Mr. Miller served as vice president for the Pacific, Asia and Africa in the international division of Abbott Laboratories, a diversified health care company, which he joined in 1976 and where he held a number of management and marketing positions. Mr. Miller formerly served as a director of Ventana Medical Systems, Inc., a developer and supplier of automated diagnostic systems. He received a B.S. degree in computer science from Purdue University, where he graduated Phi Beta Kappa.
“We are pleased to have Mark join our Board. His leadership, expertise and wisdom were crucial to the tremendous success of Stericycle. We are looking forward to him applying these skills at Accelerate Diagnostics,” commented John Patience, Accelerate Diagnostic’s Chairman.
ABOUT ACCELERATE DIAGNOSTICS
Accelerate Diagnostics, Inc is an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug resistant organisms and hospital acquired infections. We are focused on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The Company’s revolutionary BACcel(TM) platform utilizes a proprietary culture-free process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity.
In addition to the BACcel system development pipeline, Accelerate Diagnostics also owns and licenses its propriety OptiChem® surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.
Breakthrough in Retinal Implants Expected to Restore Sight to the Blind
By Pete Brown, College of Engineering | November 4, 2013
Retinal implants have not lived up to their potential, argues a joint UA-German research team, until now.Continue reading
Bridge to Transplant Patients Should Not Suffer from End-stage Biventricular Failure
Renowned Surgeon Francisco Arabia Discusses His Experience with Implantation of Over 100 SynCardia Total Artificial Hearts as it Relates to INTERMACS StatisticsContinue reading
Arizona Commerce Authority Announces 25 Semifinalists in the Fall 2013 Arizona Innovation Challenge
On November 4, 2013, the Arizona Commerce Authority (ACA) announced its 25 semifinalists in the Fall 2013 Arizona Innovation Challenge (AIC), a bi-annual business plan competition that awards the most money in the country for a technology commercialization challenge.Continue reading
Ten Arizona Legislators Named AZBio Trailblazers
Ten Arizona Legislators Named AZBio Trailblazers By The Arizona Bioindustry Association In Recognition Of Their Leadership And Actions In Support Of The Advancement Of Arizona’s Life Science And Healthcare Industry.Continue reading
Opportunity Alert:Medical Director at Celebration Stem Cell Centre
Celebration Stem Cell Centre, an AABB accredited and FDA registered public and private cord blood bank located in Gilbert, AZ is actively seeking a Medical Director.
Candidates must be a licensed physician that is qualified by training or experience in bone marrow and cord blood transplantation. The Medical Director shall have responsibility and authority for all medical activities related to procurement, processing, and provision of the cellular therapy products and related services and to ensure that these activities are compliant with AABB, FDA and NMDP requirements. The Medical Director will work closely with the current Laboratory Director and Quality Director in respect to the following responsibilities:
- Review and approval of Standard Operating Procedures (SOPs)
- Review of Nonconforming Products
- Medical Review of donor records and test results prior to product release
- Review of Proficiency testing results
- Review of validation data of new processes/procedures
- Review of Processing data when applicable
- Participation in Quarterly Quality Meetings
- Participate in Continuing Education Relevant to cord blood
All qualified individuals are encouraged to apply for this position. Please send a copy of your C.V. and cover letter to info@csccaz.com.
Landmark study of more than 27,000 women shows favorable results of Roche’s CINtec PLUS cytology test
PALMS study finds dual-biomarker test to be highly sensitive and specific for cervical precancersContinue reading
FDA Approves First Breakthrough Therapy – Genentech’s Gazyva(TM)
FDA Approves Gazyva™ (Obinutuzumab) for People With Previously Untreated Chronic Lymphocytic Leukemia (CLL)Continue reading